Dr Reddy's: Semaglutide batches out of spec, supply delayed

Dr Reddy's Laboratories Ltd announced that certain batches of its semaglutide product were found to be out of specification due to an issue with the active pharmaceutical ingredient (API). The company is investigating the root cause and implementing corrective measures. Commercial supplies of the product will be temporarily delayed. Importantly, there is no impact on patient safety or existing global regulatory filings. Dr Reddy's remains committed to reliable global supplies of this metabolic therapy and will host a conference call to discuss the matter.